NRP104

DRUG5 trials

Conditions

Amphetamine-Related DisordersAttention Deficit Disorder With HyperactivityAttention Deficit Disorders With HyperactivityAttention Deficit Hyperactivity DisorderAttention Deficit Hyperactivity DisordersSubstance-Related Disorders

Phase 1

Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse

CompletedNCT00248092

New River PharmaceuticalsAmphetamine-Related Disorders, Attention Deficit Disorder With Hyperactivity, Substance-Related Disorders

Start: 2006-01-31End: 2006-05-31Target: 36Updated: 2007-11-05

Phase 2

Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories

CompletedNCT00247572

New River PharmaceuticalsAmphetamine-Related Disorders, Attention Deficit Disorder With Hyperactivity, Substance-Related Disorders

Start: 2005-09-30End: 2005-11-30Target: 12Updated: 2007-11-05

NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD

CompletedNCT00557011

New River PharmaceuticalsAttention Deficit Disorder With Hyperactivity

Start: 2004-09-30End: 2004-12-31Updated: 2011-05-25

Phase 3

Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

CompletedNCT00334880

New River PharmaceuticalsAttention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorder, Attention Deficit Hyperactivity Disorders

Start: 2006-05-31End: 2006-11-30Updated: 2009-07-02

Phase 3 Randomized Double-Blind Placebo-Controlled Study of NRP104 in Children Aged 6-12 With ADHD

CompletedNCT00556296

New River PharmaceuticalsAttention Deficit Hyperactivity Disorder

Start: 2004-10-31End: 2005-09-30Updated: 2011-06-21

Phase 3 Randomized Double-Blind Placebo-Controlled Study of NRP104 in Children Aged 6-12 With ADHD

CompletedNCT00556296

New River PharmaceuticalsAttention Deficit Hyperactivity Disorder

Start: 2004-10-31End: 2005-09-30Updated: 2011-06-21

Journal of Managed Care & Specialty Pharmacy2024-06-017 citations

Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder

UNC Libraries2020-10-31

Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder

UNC Libraries2020-10-31

Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.

2013-01-2924 citations

Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study.

2012-12-199 citations

Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis.

2011-11-0422 citations

Prediction of placebo response in 2 clinical trials of lisdexamfetamine dimesylate for the treatment of ADHD.

2011-10-0116 citations

Impact of stimulant pharmacotherapy on sleep quality: post hoc analyses of 2 large, double-blind, randomized, placebo-controlled trials.

2011-07-0134 citations

Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.

2009-12-0131 citations

Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder.

2009-08-0328 citations

A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder.

2009-06-0994 citations

NRP104

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Related Papers